What is Enovis's prevention & recovery — depreciation?

Enovis (ENOV) reported prevention & recovery — depreciation of $5.13M in Q2 2026.

What does prevention & recovery — depreciation mean?

This metric tracks the periodic allocation of the cost of tangible assets used within the Prevention & Recovery segment over their useful lives. It reflects the wear and tear or obsolescence of manufacturing equipment and infrastructure dedicated to rehabilitation and pain management products. Analyzing this expense provides insight into the capital intensity of the segment and the ongoing investment required to maintain its operational capacity.

Enovis (ENOV) Prevention & Recovery — Depreciation

Screener

Other segment segments

Reconstructive

$23.69M-1.1%

Similar metrics at other companies

SUNBSpecialty — Depreciation

$141M+6.0%

SUNBU.K. — Depreciation

$43M+2.4%

CATOCredit — Depreciation

$0—

CATORetail — Depreciation

$2.24M-12.8%

CPH

CPHCDevelopment — Depreciation

$0—

CCKOther — Depreciation

$7M0.0%

Other financials

Income statement

See full

Revenue$582.8M+3.2%

Gross profit$359.2M+7.3%

Operating income$17.4M+204%

Net income-$1.2M+96.8%

EPS (diluted)-$0.02+96.9%

Balance sheet

See full

Cash & equivalents$12.6M-71.5%

Total debt$1.3B-6.4%

Total equity$1.5B-42.7%

Total assets$3.8B-25.0%

Cash flow

See full

Operating cash flow$75.0M+57.1%

CapEx$43.9M-1.1%

Free cash flow$31.1M—

Valuation

See full

Market cap$1.53B-5.5%

Enterprise value$2.83B-4.9%

P/S0.7×-0.1×

Profitability

See full

Gross margin61.1%+3.5pp

Operating margin-45.1%+19.4pp

Net margin-48%+17.7pp

FCF margin-3.1%-1.1pp

Returns & leverage

See full

Return on equity-54.3%+672pp

Debt / equity0.9×+0.3×

Current ratio2×-0.3×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The source filing: Enovis’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 6:45 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001420800-26-000035

Line item	Three Months Ended / July 3, 2026	Three Months Ended / July 4, 2025	Six Months Ended / July 3, 2026	Six Months Ended / July 4, 2025
Segment research and development	7,706	9,669	15,453	18,910
Segment operating expense	111,250	107,523	223,720	215,367
Total segment expenses	243,050	248,528	489,024	494,377
Add: Depreciation	5,129	4,689	10,194	8,857
Adjusted EBITDA (non-GAAP)	$50,327	$46,731	$81,436	$77,634
Reconstructive:
Net sales	$294,534	$273,975	$611,667	$560,225
Segment cost of sales	98,873	97,750	196,208	195,024

Item 1. Financial Statements

FAQ

What is Enovis's prevention & recovery — depreciation?: Enovis (ENOV) reported prevention & recovery — depreciation of $5.13M in Q2 2026.
What does prevention & recovery — depreciation mean?: This metric tracks the periodic allocation of the cost of tangible assets used within the Prevention & Recovery segment over their useful lives. It reflects the wear and tear or obsolescence of manufacturing equipment and infrastructure dedicated to rehabilitation and pain management products. Analyzing this expense provides insight into the capital intensity of the segment and the ongoing investment required to maintain its operational capacity.